Literature DB >> 17585539

Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.

Aldona Kasprzak1, Maciej Zabel, Wiesława Biczysko.   

Abstract

Neuroendocrine tumours of lungs represent a subgroup of pulmonary tumours with typical morphofunctional traits. In light microscopy, the four principal types of the tumours (typical and atypical carcinoids, small cell lung cancer, large cell neuroendocrine carcinoma) demonstrate typical arrangement of cells (organoid nesting, palisading, a trabecular pattern, and rosette-like structures), variable number of mitoses, presence or absence of necrosis. In ultrastructure, neuroendocrine tumours manifest groups of cells with cytoplasmic granules (and the so called dense-core neurosecretory granules in particular). Neuroendocrine cells release hormones to circulation or in a paracrine manner. Some pulmonary tumours exhibit no neuroendocrine morphology at the level of light microscopy but demonstrate ultrastructural and/or immunohistochemical traits of neuroendocrine differentiation. Proteins the presence of which confirms neuroendocrine origin of the tumours have been found relatively early to include neuron-specific enolase (NSE), the group of chromogranins and synaptophysin. Present study aimed at summing up results of investigations conducted in, approximately, recent 30 years pertaining expression and/or serum concentrations of four neuroendocrine markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) and at an attempt to evaluate the role of such studies in extension of diagnostic and prognostic potential as related to neuroendocrine pulmonary tumours. Until now, the most sensitive and specific marker or marker combination for early detection of neuroendocrine subtypes of lung tumours has not been identified. All of the markers examined in present study were detected both in the typical neuroendocrine pulmonary tumours and in a certain proportion of non-endocrine tumours. In the case of chromogranin A improved sensitivity and specificity of immunocytochemical studies was obtained using a panel of antibodies directed to various epitopes of the protein. Both in endocrine and non-endocrine tumours, neuron-specific enolase (NSE) is thought to represent mainly a prognostic index, and only quantitation of serum concentrations of the protein or of the fraction of immunopositive cells may permit to differentiate between subtypes of the tumours. Synaptophysin is regarded to represent one of the most specific markers of neuroendocrine differentiation, manifesting a much higher sensitivity than chromogranin A and NSE. With increasing frequency, PGP 9.5 is regarded to provide a prognostic marker in diagnosis of non-small cell lung carcinomas rather than of typical neuroendocrine tumours.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585539

Source DB:  PubMed          Journal:  Pol J Pathol        ISSN: 1233-9687            Impact factor:   1.072


  16 in total

1.  Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

Authors:  J Zou; Q Li; F Kou; Y Zhu; M Lu; J Li; Z Lu; L Shen
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.

Authors:  Nadiya Sosonkina; Seung-Keun Hong; Dmytro Starenki; Jong-In Park
Journal:  Genes Genomics       Date:  2014-12       Impact factor: 1.839

3.  Gamma-enolase predicts lung damage in severe acute pancreatitis-induced acute lung injury.

Authors:  Lawrence Owusu; Caiming Xu; Hailong Chen; Geliang Liu; Guixin Zhang; Jinwen Zhang; Zhankai Tang; Zhongwei Sun; Xin Yi
Journal:  J Mol Histol       Date:  2018-05-04       Impact factor: 2.611

4.  Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.

Authors:  Gianfranco Alpini; Pietro Invernizzi; Eugenio Gaudio; Julie Venter; Shelley Kopriva; Francesca Bernuzzi; Paolo Onori; Antonio Franchitto; Monique Coufal; Gabriel Frampton; Domenico Alvaro; Sum P Lee; Marco Marzioni; Antonio Benedetti; Sharon DeMorrow
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

5.  Primary small cell neuroendocrine carcinoma of vagina: a rare case report.

Authors:  Jignasa N Bhalodia; Dhiren V Kapapura; Malay N Parekh
Journal:  Patholog Res Int       Date:  2011-10-03

6.  Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma.

Authors:  Xin-Ke Zhang; Tao Qin; Yin-Duo Zeng; Yuan-Yuan Zhao; Xue Hou; Wen-Feng Fang; Shao-Dong Hong; Ting Zhou; Zhi-Huang Hu; Yun-Peng Yang; Yu-Xiang Ma; Cong Xue; Yan Huang; Hong-Yun Zhao; Li Zhang
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

Review 7.  Gamma-enolase: a well-known tumour marker, with a less-known role in cancer.

Authors:  Tjasa Vizin; Janko Kos
Journal:  Radiol Oncol       Date:  2015-08-21       Impact factor: 2.991

Review 8.  Paraneoplastic syndromes in olfactory neuroblastoma.

Authors:  Michał Kunc; Anna Gabrych; Piotr Czapiewski; Krzysztof Sworczak
Journal:  Contemp Oncol (Pozn)       Date:  2015-03-26

9.  NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy.

Authors:  Jianbo Li; Hongman Zhang; Min Xie; Lingfei Yan; Jiawei Chen; Hongxing Wang
Journal:  Diabetes Care       Date:  2013-07-11       Impact factor: 19.112

10.  Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.

Authors:  Anirban Das; Abhishek Pratap
Journal:  Case Rep Oncol Med       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.